The Caris Precision Oncology Alliance™ (POA) convenes the brightest minds in oncology, cancer care, clinical research, and drug development. The vision statement of the POA is to build the best-in-class collaborative research network focusing on precision oncology to identify predictive and prognostic markers that help in improving the outcomes and clinical care of patients with cancer. The POA aims to deliver molecular science solutions to promote clinical trials that cultivate combined clinical-genomic data and collaborative research to advance the science of cancer care. The alliance is comprised of a growing network of leading cancer centers from across the country that demonstrate a commitment to precision medicine and work collaboratively to:
- Integrate molecular testing where appropriate into cancer care and patient treatment management
- Collaborate on research studies and clinical trials
- Track longitudinal clinical outcomes, contribute data, and correlate outcomes with molecular clinical demographic attributes
- Publish innovative abstracts and manuscripts in top-tier journals promoting academic advancement in molecular profiling and its impact on clinical care
It’s important for oncologists and patients to know that their data is available to them for analysis. Our database of clinical outcomes is populated with anonymized data from POA member institutions and from commercially available data. This continuous feedback loop between finding new biomarkers and interpreting their significance, provides insights for drug developers, which ultimately feeds back into our system and directly helps patients.